雄激素受体对雌激素受体阳性乳腺癌细胞增殖的抑制作用

被引:12
作者
朱蔼瑜
许宇媚
许晶
唐林
张群
管晓翔
机构
[1] 南方医科大学金陵医院(南京军区南京总医院)肿瘤内科
关键词
雄激素受体; 乳腺癌; 细胞增殖; 细胞凋亡;
D O I
暂无
中图分类号
R737.9 [乳腺肿瘤];
学科分类号
100214 [肿瘤学];
摘要
目的雄激素受体(androgen receptor,AR)在乳腺癌中广泛表达,并影响乳腺癌细胞的增殖。文中旨在探讨AR在雌激素受体(estrogen receptor,ER)阳性乳腺癌细胞中的作用。方法选取生长状态良好的MCF-7细胞随机分成3组,分别给予不同的处理,双氢睾酮组:加入双氢睾酮及DMSO溶液;比卡鲁胺组:加入比卡鲁胺及无水乙醇溶液;对照组:无水乙醇及DMSO溶液;保证每组无水乙醇及DMSO溶液浓度相同。用噻唑蓝比色法、细胞计数、流式细胞术观察细胞增殖和凋亡改变,并用免疫印迹检测细胞周期调控相关基因的表达改变。结果免疫印迹结果显示,双氢睾酮组AR相对灰度值(1.055±0.020)较对照组(0.795±0.020)显著升高(P<0.05),而比卡鲁胺组(0.705±0.010)则较对照组明显降低(P<0.05)。流式细胞结果显示:与对照组乳腺癌细胞早期凋亡率[(3.540±0.375)%]相比,双氢睾酮组[(5.120±0.312)%]显著增加(P<0.01),而比卡鲁胺组[(2.410±0.367)%]明显减小(P<0.01)。与对照组比较,双氢睾酮组MCF-7细胞中p53、p73、p21蛋白表达升高,而比卡鲁胺组细胞中p53、p73、p21蛋白表达有所下降,差异有统计学意义(P<0.05)。结论 AR在ER阳性乳腺癌中发挥抑制肿瘤生长的作用,预示AR有可能成为ER阳性乳腺癌治疗的一个潜在靶点。
引用
收藏
页码:354 / 358
页数:5
相关论文
共 13 条
[1]
干扰素诱导蛋白AIM2诱发乳腺癌细胞凋亡的分子机制 [J].
刘志勇 ;
易坚 ;
刘凤恩 .
医学研究生学报, 2015, 28 (07) :696-700
[2]
p53在乳腺癌中的表达意义及5-氮杂脱氧胞苷对p53的调控作用 [J].
赖静 ;
顾军 ;
许晶 ;
吴波 ;
张文文 ;
聂伟伟 ;
宋伟 ;
汪泽兴 ;
黄桂春 ;
管晓翔 .
医学研究生学报, 2014, 27 (06) :573-576
[3]
Phase II Trial of Bicalutamide in Patients with Androgen Receptor–Positive; Estrogen Receptor–Negative Metastatic Breast Cancer.[J].Ayca Gucalp;Sara Tolaney;Steven J. Isakoff;James N. Ingle;Minetta C. Liu;Lisa A. Carey;Kimberly Blackwell;Hope Rugo;Lisle Nabell;Andres Forero;Vered Stearns;Ashley S. Doane;Michael Danso;Mary Ellen Moynahan;Lamia F. Momen;Joseph M. Gonzalez;Arooj Akhtar;Dilip D. Giri;Sujata Patil;Kimberly N. Feigin;Clifford A. Hudis;Tiffany A. Traina.Clinical Cancer Research.2013, 1
[4]
Selective oestrogen receptor modulators in prevention of breast cancer: an updated meta-analysis of individual participant data [J].
Cuzick, Jack ;
Sestak, Ivana ;
Bonanni, Bernardo ;
Costantino, Joseph P. ;
Cummings, Steve ;
DeCensi, Andrea ;
Dowsett, Mitch ;
Forbes, John F. ;
Ford, Leslie ;
LaCroix, Andrea Z. ;
Mershon, John ;
Mitlak, Bruce H. ;
Powles, Trevor ;
Veronesi, Umberto ;
Vogel, Victor ;
Wickerham, D. Lawrence .
LANCET, 2013, 381 (9880) :1827-1834
[5]
The AR dependent cell cycle: Mechanisms and cancer relevance.[J].Matthew J. Schiewer;Michael A. Augello;Karen E. Knudsen.Molecular and Cellular Endocrinology.2011, 1-2
[6]
Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies [J].
Lehmann, Brian D. ;
Bauer, Joshua A. ;
Chen, Xi ;
Sanders, Melinda E. ;
Chakravarthy, A. Bapsi ;
Shyr, Yu ;
Pietenpol, Jennifer A. .
JOURNAL OF CLINICAL INVESTIGATION, 2011, 121 (07) :2750-2767
[7]
Targeting Androgen Receptor in Estrogen Receptor-Negative Breast Cancer [J].
Ni, Min ;
Chen, Yiwen ;
Lim, Elgene ;
Wimberly, Hallie ;
Bailey, Shannon T. ;
Imai, Yuuki ;
Rimm, David L. ;
Liu, X. Shirley ;
Brown, Myles .
CANCER CELL, 2011, 20 (01) :119-131
[8]
Androgen receptor expression is a significant prognostic factor in estrogen receptor positive breast cancers [J].
Castellano, Isabella ;
Allia, Elena ;
Accortanzo, Valeria ;
Vandone, Anna Maria ;
Chiusa, Luigi ;
Arisio, Riccardo ;
Durando, Antonio ;
Donadio, Michela ;
Bussolati, Gianni ;
Coates, Alan S. ;
Viale, Giuseppe ;
Sapino, Anna .
BREAST CANCER RESEARCH AND TREATMENT, 2010, 124 (03) :607-617
[9]
Antiproliferative actions of the synthetic androgen; mibolerone; in breast cancer cells are mediated by both androgen and progesterone receptors.[J].Elisa J. Cops;Tina Bianco-Miotto;Nicole L. Moore;Christine L. Clarke;Stephen N. Birrell;Lisa M. Butler;Wayne D. Tilley.Journal of Steroid Biochemistry and Molecular Biology.2008, 3
[10]
A functionally significant cross-talk between androgen receptor and ErbB2 pathways in estrogen receptor negative breast cancer [J].
Naderi, Ali ;
Hughes-Davies, Luke .
NEOPLASIA, 2008, 10 (06) :542-548